#United States #New York #Pomerantz LLP #Rocket Pharmaceuticals #RP-A501

Pomerantz Law Firm Launches Investigation into Rocket Pharmaceuticals Investors

The Pomerantz Law Firm, a renowned name in corporate litigation, has announced that it is investigating potential claims on behalf of investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This investigation arises amidst serious concerns regarding allegations of securities fraud and other unlawful business practices involving key executives at Rocket.

In a press release dated May 27, 2025, Rocket Pharmaceuticals revealed an update concerning their investigational gene therapy, RP-A501, which is intended to treat Danon disease. This update was particularly alarming as it disclosed that a patient involved in the Phase 2 pivotal trial experienced an unexpected Serious Adverse Event (SAE). The complications stemmed from a condition known as capillary leak syndrome. Upon awareness of this critical event, Rocket voluntarily decided to pause any further dosing in the ongoing study. The situation escalated as the FDA subsequently placed a clinical hold on the trial to allow for further evaluation of the circumstances surrounding the SAE.

Tragically, the patient in question has since died after battling an acute systemic infection, raising further questions about the drug's safety and the company's reporting practices. Following this news, Rocket’s stock plummeted by $3.94 per share, marking a staggering 62.84% drop to a closing price of $2.33 per share on the day the announcement was made.

The severity of these incidents has led Pomerantz to advise investors to reach out to the firm for potential actions regarding their investments in Rocket Pharmaceuticals. Investors can contact attorney Danielle Peyton directly via email at [email protected] or by calling 646-581-9980, ext. 7980. The firm is actively looking into whether Rocket and its key officers or directors engaged in any misconduct that could be considered detrimental to investors' interests.

Founded by the late Abraham L. Pomerantz, a pioneer in the class action bar, Pomerantz LLP is known for its dedication to safeguarding the rights of investors and securing compensation for victims affected by securities fraud, breaches of fiduciary duty, and other forms of corporate wrongdoing. With over 85 years of experience, the firm has established a solid reputation for recovering substantial damages on behalf of its clients. This investigation may add to the firm’s extensive history of fighting for justice in the financial markets.

Pomerantz continues to seek the truth behind Rocket Pharmaceuticals' recent turmoil and will take appropriate action if evidence supports the claims of wrongdoing. Investors who are concerned about their investments should not hesitate to reach out and explore their options for joining potential class actions.

For more information about Pomerantz and its legal services, visit their official website at www.pomlaw.com.

Important Notes:

• - This article serves as a notice regarding an investigation and should not be interpreted as legal advice. Previous results do not guarantee similar outcomes for current or future cases.
• - Interested investors should act promptly due to the evolving nature of this situation.